Brief news reports on Tuberculosis

Call for Alternate Board Member: Communities Delegation to Unitaid Board

The Communities Delegation to the Unitaid Board is looking to appoint a new Alternate Board Member to represent communities living with and affected by HIV, TB and malaria and those co-infected with HIV and HCV.

Read More →

Time for $5 Coalition statement: Cepheid’s updated GeneXpert pricing does not address country needs

The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.

Read More →

TB immune response discovery could significantly reduce disease harm

A pioneering study by UCL scientists has discovered the presence of a harmful inflammatory protein in patients with symptomatic tuberculosis (TB).

Read More →

Pravastatin may have protective effect against active TB infection

Risk for active tuberculosis (TB) may be reduced with the use of statins. This finding was published in a letter to the editor in the Journal of Infectious Diseases.1

Read More →

Needs assessment survey: Online course on new TB tools

The Stop TB Partnership New Tools Working Groups and the Stop TB Partnership NGO and Affected Community Board Delegations are co-developing a self-guided online learning course on new TB drugs, diagnostics, and vaccines. The purpose of the course is to build capacity and strengthen the engagement of advocates, including TB-affected communities and civil society, in the TB research and development agenda.

Read More →

Development of updated WHO guidelines on the management of TB in children and adolescents

The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the management of tuberculosis (TB) in children and adolescents.

Read More →

Landmark TB trials results published in New England Journal of Medicine

A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.

Read More →

Performance of TB biomarker for targeted preventative therapy

An RNA signature of tuberculosis, RISK11, was used to discriminate between individuals with prevalent tuberculosis or progression to incident tuberculosis and individuals who remained healthy, according to a study in The Lancet Infectious Diseases. However, the use of 3 months of once-weekly high-dose isoniazid and rifapentine (3HP) to treat signature-positive individuals did not reduce progression to tuberculosis over 15 months.

Read More →

PPM Working Group Mini-Meet

A special Mini-Meet of the Working Group on Public-Private Mix for TB Prevention and Care (PPM Working Group) will be held virtually on 20 May 2021 in an interactive format. The meeting is open to all participants.

Read More →

Call for applications! Malaria, hepatitis C, and latent TB infection long-acting technologies community advisory board

TAG and AfroCAB are inviting applications from treatment activists and community leaders for a new cross-disease long-acting technologies community advisory board. The deadline to apply is 21 May 2021.

Read More →

Page 1 of 751 · Total posts: 10

1 2 Last→